8-K: MariMed Restructures $14.2M Obligation, Issues New Debt & Preferred Stock

MariMed Inc. has restructured a $14.2 million obligation to Navy Capital, converting it into $8 million in new promissory notes and 26.9 million shares of new convertible preferred stock.

Summary

• MariMed Inc. (the Company) entered into a Restructuring and Exchange Agreement with Navy Capital Green International, Ltd. and its affiliates (Navy) on February 24, 2026.
• The agreement addresses and extinguishes a mandatory conversion obligation of approximately $14.2 million (the Series B Obligation) related to previously issued Series B Convertible Preferred Stock.
• The original Series B Preferred Stock, issued in February 2020, would have automatically converted on February 28, 2026, requiring the Company to pay the difference between a $3.00 per share original value and the 60-day VWAP (approximately $0.1018 per share).
• In exchange for cancelling the old Series B Preferred Stock and extinguishing the $14.2 million obligation, the Company issued Navy two new promissory notes totaling $8,000,000.
• Note #1 is for $2,000,000, due March 1, 2028, accruing interest at 8.0% per annum.
• Note #2 is for $6,000,000, due March 1, 2031, accruing interest at 10.0% per annum, which can be reduced to 8% if Note #1 is paid in full within six months of February 24, 2026.
• The Company also issued 26,900,000 shares of a new class of Series B Convertible Preferred Stock (New Series B Preferred Stock) to Navy, with an aggregate liquidation preference of $6,725,000 ($0.25 per share).
• The New Notes are guaranteed by certain subsidiaries of the Company.
• The New Series B Preferred Stock is non-voting but grants holders certain protective rights, including requiring consent for charter amendments, liquidation, or creation of senior stock.
• The New Series B Preferred Stock ranks senior to Common Stock for dividend and liquidation rights.
• New Series B Holders have the option to convert their shares into Common Stock on a one-for-one basis at any time on or prior to the five-year anniversary of issuance.
• The Company has the option to convert all New Series B Preferred Stock into Common Stock on a one-for-one basis if the daily VWAP exceeds $2.00 per share for at least 20 consecutive trading days and average daily volume is at least 400,000 shares.
• Automatic conversion of the New Series B Preferred Stock occurs on February 25, 2031, with various options for the Company depending on the 60-day VWAP relative to $0.25 per share, potentially involving cash payments or conversion at a variable ratio.
• The issuance of the New Series B Preferred Stock was made in reliance on Section 4(a)(2) of the Securities Act of 1933 and Regulation D.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but costly restructuring. While it provides immediate liquidity relief by avoiding a large cash payout, it introduces new debt with high interest rates and significant potential for future equity dilution at a much lower valuation, reflecting ongoing financial strain.

Positives

• The Company successfully restructured an immediate $14.2 million cash payment obligation, deferring a significant liquidity event.
• The original Series B Preferred Stock and its associated obligation were extinguished, removing a substantial near-term financial burden.
• The new preferred stock has a lower per-share liquidation preference ($0.25) compared to the original $3.00 per share value of the old preferred stock, reflecting a more current market valuation.

Negatives

• The restructuring introduces $8,000,000 in new debt with interest rates of 8.0% and 10.0% (potentially 8%), adding to the Company's financial liabilities and ongoing interest expenses.
• The issuance of 26,900,000 shares of New Series B Preferred Stock represents a significant potential for future dilution if converted into common stock.
• The Company's option to force conversion of the New Series B Preferred Stock is contingent on the common stock's VWAP exceeding $2.00, which is substantially higher than the current approximate $0.1018 VWAP, indicating a challenging path to non-dilutive conversion.
• The new preferred stock grants Navy Capital significant protective rights, including consent requirements for key corporate actions, which could limit management's flexibility.

Risks

• Failure to make timely payments on the New Notes could trigger an Event of Default, leading to acceleration of the entire principal and accrued interest.
• The Company faces the risk of significant dilution if the New Series B Preferred Stock converts to common stock, especially if the stock price remains low, as the conversion terms allow for a 1:1 conversion at the holder's option.
• The Company's ability to reduce the interest rate on Note #2 from 10% to 8% is contingent on paying Note #1 in full within six months, which may strain short-term liquidity.
• The Company is exposed to default risks related to other debt if liabilities exceeding $500,000 become due and payable prematurely.
• Pension plan liabilities or liens exceeding $100,000 could also trigger an Event of Default.
• Judgments, orders, decrees, or arbitration awards against the Company and its subsidiaries aggregating over $500,000, if not covered by insurance or stayed, pose a default risk.

Future Outlook

The restructuring provides MariMed with immediate relief from a significant cash obligation, converting it into a combination of longer-term debt and preferred equity. The Company's ability to force conversion of the new preferred stock is tied to a substantial increase in its common stock price, indicating a long-term goal for equity appreciation. The new debt obligations will require consistent cash flow for interest and principal payments over the next several years.

Management Comments

• Jon Levine, Chief Financial Officer, signed the filing on behalf of MariMed Inc.

Industry Context

StockSavvy.ai notes that this restructuring reflects the ongoing financial challenges faced by some companies in the cannabis industry, particularly those that raised capital during earlier, more optimistic market conditions. The need to renegotiate and defer significant obligations, often at less favorable terms for existing equity holders, is a common theme as the industry matures and capital markets become more discerning. The terms of this deal suggest a company navigating a difficult financial landscape, seeking to optimize its capital structure to ensure continued operations amidst regulatory complexities and market volatility.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The entire restructuring transaction is with Navy Capital Green International, Ltd. and its affiliates (Navy), which previously held significant preferred stock and provided loans to the Company. This constitutes a material related party transaction.

Stakeholder Impact

• **Shareholders (Common Stock)**: Face potential significant dilution from the conversion of 26.9 million shares of New Series B Preferred Stock. The terms of the restructuring reflect a lower effective valuation for the preferred equity compared to the original issuance, indicating a challenging environment for common shareholders.
• **Creditors (New Notes Holders)**: Navy Capital, as the holder of the New Notes, benefits from an $8 million debt instrument with fixed interest rates (8-10%) and a subsidiary guaranty, providing a more secure position than the previous preferred equity obligation.
• **Company (Management/Operations)**: Gains immediate liquidity relief by avoiding a $14.2 million cash payout, providing a runway to focus on operations. However, it takes on new debt obligations and the potential for future dilution, requiring careful financial management.

Next Steps

• The Company will make monthly principal and interest payments on the New Notes, commencing March 1, 2026.
• The Company may choose to pay Note #1 in full within six months of February 24, 2026, to reduce the interest rate on Note #2 to 8.0%.
• New Series B Holders have the option to convert their shares into Common Stock on a one-for-one basis at any time on or prior to February 24, 2031.
• The Company has the option to convert all New Series B Preferred Stock into Common Stock if specific stock price and volume conditions are met (VWAP > $2.00 for 20 consecutive trading days and average daily volume > 400,000 shares).
• All outstanding shares of New Series B Preferred Stock will automatically convert into Common Stock on February 25, 2031, under terms that may involve cash payments or variable conversion ratios depending on the 60-day VWAP.

Key Dates

Recommendation

The restructuring provides MariMed with immediate relief from a substantial cash obligation, which is a short-term positive for liquidity. However, it introduces new debt with significant interest payments and a large block of preferred stock that could lead to substantial dilution if the common stock price does not recover significantly. The terms reflect a company in a challenging financial position, but the restructuring provides a necessary runway. Investors should hold to monitor the Company's ability to improve its operational performance and achieve the stock price appreciation needed to mitigate future dilution and manage its new debt obligations.

Keywords

MariMed Inc., Navy Capital, Debt Restructuring, Convertible Preferred Stock, Promissory Notes, SEC Filing, 8-K, Corporate Finance, Equity Financing, Cannabis Industry